IHL-675A Reveals Promising Safety and Pharmacokinetic Profile, with Mark Bleackley, PhD

Results demonstrated IHL-675A was well-tolerated, with no concerning adverse events or serious adverse events reported.

Related Keywords

,Mark Bleackley ,Incannex Healthcare ,World Health Organization ,Chief Scientific Officer ,Incannex Healthcare Limited ,